Our integrated AAV discovery process is designed to produce optimized gene therapies

Our technologies aim to improve manufacturing fidelity and to minimize the risks of immunogenicity and toxicity

Our one-time gene therapy candidates are configured to fundamentally change how many diseases are treated

Best-in-class Capsids

We identify novel AAV capsid variants at substructure- and cells-specific resolution to advance gene therapies with increased potency and specificty

imagesteps image
Identify disease- and target-specific substructure
imagesteps image
Select optimal route for clinical administration (RoA)
imagesteps image
Our proprietary platforms enable discovery of novel tissue- and cell-specific capsids
image
Engineer specific payload expression using proprietary promoters and regulatory elements
Potent, specific & manufacturable

Multiple campaigns have identified unique AAV capsid variants with ideal characteristics to address specific diseases

image
Deep Brain
image
Ependyma
image
Ear
image
Pan-Neuronal
image
Eye
image
muscle
image
Heart
image
kidney
IMPROVED EFFICACY, SAFETY & ACCESSibility

Our novel AAV capsid variants have the potential to unlock significant clinical benefit and commercial upside

Flow ImageFlow Image
harnessing ai/ML

NHP screens for unique delivery zip codes coupled with computational models to optimize AAV gene therapies for virtually any tissue or cell type

NHP screens for unique delivery zip codes coupled with computational models to optimize AAV gene therapies for virtually
any tissue or cell type

How WE ARE DIFFERENT

Redefining AAV: high precision, low dose, rapid manufacturing

By employing proprietary AAV capsid variants with enhanced potency and specificity, our gene therapy candidates are designed to reduce dose requirements and to improve safety, efficacy, manufacturing, and costs

The Latus Solution

We engineer capsids matched to optimized routes of administration to reduce AAV doses

IMPROVED AAV MANUFACTURING

Latus’ approach enables massive reductions in AAV manufacturing requirements

Uniquely competitive offering to advance AAV therapeutics from ultra-rare to common disease indications

*AAV Vector Market, Root Analysis, 2022
*AAV Vector Market, Root Analysis, 2022
*AAV Vector Market, Root Analysis, 2022
**Barrett, Endpoints News, 2022
Learn more about our programs